SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
FRA:56S1 - Deutsche Boerse Ag - FR0013154002 - Common Stock - Currency: EUR
We assign a fundamental rating of 4 out of 10 to 56S1. 56S1 was compared to 15 industry peers in the Life Sciences Tools & Services industry. 56S1 has only an average score on both its financial health and profitability. 56S1 is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
56S1 had positive earnings in the past year.
In the past year 56S1 had a positive cash flow from operations.
56S1 had positive earnings in each of the past 5 years.
In the past 5 years 56S1 always reported a positive cash flow from operatings.
1.2 Ratios
56S1 has a Return On Assets of 2.12%. This is comparable to the rest of the industry: 56S1 outperforms 47.06% of its industry peers.
56S1 has a Return On Equity (4.38%) which is comparable to the rest of the industry.
With a Return On Invested Capital value of 4.03%, 56S1 is not doing good in the industry: 64.71% of the companies in the same industry are doing better.
The Average Return On Invested Capital over the past 3 years for 56S1 is above the industry average of 6.82%.
The last Return On Invested Capital (4.03%) for 56S1 is well below the 3 year average (10.41%), which needs to be investigated, but indicates that 56S1 had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.12% | ||
| ROE | 4.38% | ||
| ROIC | 4.03% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
56S1's Profit Margin of 6.29% is fine compared to the rest of the industry. 56S1 outperforms 70.59% of its industry peers.
56S1's Profit Margin has declined in the last couple of years.
The Operating Margin of 56S1 (13.32%) is comparable to the rest of the industry.
In the last couple of years the Operating Margin of 56S1 has declined.
56S1 has a Gross Margin (43.40%) which is comparable to the rest of the industry.
56S1's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.32% | ||
| PM (TTM) | 6.29% | ||
| GM | 43.4% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 56S1 is creating some value.
The number of shares outstanding for 56S1 has been increased compared to 1 year ago.
56S1 has more shares outstanding than it did 5 years ago.
56S1 has a better debt/assets ratio than last year.
2.2 Solvency
56S1 has an Altman-Z score of 3.91. This indicates that 56S1 is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of 56S1 (3.91) is better than 64.71% of its industry peers.
The Debt to FCF ratio of 56S1 is 6.04, which is on the high side as it means it would take 56S1, 6.04 years of fcf income to pay off all of its debts.
56S1 has a Debt to FCF ratio (6.04) which is in line with its industry peers.
A Debt/Equity ratio of 0.70 indicates that 56S1 is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.70, 56S1 is not doing good in the industry: 70.59% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 6.04 | ||
| Altman-Z | 3.91 |
ROIC/WACC0.52
WACC7.81%
2.3 Liquidity
56S1 has a Current Ratio of 1.85. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Current ratio value of 1.85, 56S1 is doing good in the industry, outperforming 70.59% of the companies in the same industry.
56S1 has a Quick Ratio of 1.12. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.12, 56S1 perfoms like the industry average, outperforming 58.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
56S1 shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.47%.
56S1 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 4.19% yearly.
The Revenue has been growing slightly by 0.16% in the past year.
56S1 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.05% yearly.
EPS 1Y (TTM)-16.47%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%43.06%
Revenue 1Y (TTM)0.16%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%6.3%
3.2 Future
56S1 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.18% yearly.
Based on estimates for the next years, 56S1 will show a quite strong growth in Revenue. The Revenue will grow by 12.44% on average per year.
EPS Next Y24.02%
EPS Next 2Y24.95%
EPS Next 3Y24.29%
EPS Next 5Y22.18%
Revenue Next Year9.64%
Revenue Next 2Y10.58%
Revenue Next 3Y10.89%
Revenue Next 5Y12.44%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 55.17, which means the current valuation is very expensive for 56S1.
Compared to the rest of the industry, the Price/Earnings ratio of 56S1 indicates a slightly more expensive valuation: 56S1 is more expensive than 76.47% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of 56S1 to the average of the S&P500 Index (29.35), we can say 56S1 is valued expensively.
Based on the Price/Forward Earnings ratio of 44.49, the valuation of 56S1 can be described as expensive.
Based on the Price/Forward Earnings ratio, 56S1 is valued a bit more expensive than 70.59% of the companies in the same industry.
56S1's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.10.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 55.17 | ||
| Fwd PE | 44.49 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 56S1 is valued a bit more expensive than 76.47% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, 56S1 is valued a bit more expensive than 64.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 39.54 | ||
| EV/EBITDA | 31.2 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 56S1 does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as 56S1's earnings are expected to grow with 24.29% in the coming years.
PEG (NY)2.3
PEG (5Y)13.15
EPS Next 2Y24.95%
EPS Next 3Y24.29%
5. Dividend
5.1 Amount
56S1 has a yearly dividend return of 0.35%, which is pretty low.
Compared to an average industry Dividend Yield of 0.79, 56S1 has a dividend in line with its industry peers.
With a Dividend Yield of 0.35, 56S1 pays less dividend than the S&P500 average, which is at 2.33.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.35% |
5.2 History
The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
38.39% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
56S1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP38.39%
EPS Next 2Y24.95%
EPS Next 3Y24.29%
FRA:56S1 (3/7/2025, 7:00:00 PM)
193.1
+0.4 (+0.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.63%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.79B
Analysts76.67
Price Target256.9 (33.04%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.35% |
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP38.39%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.01%
Min EPS beat(2)-5.62%
Max EPS beat(2)7.63%
EPS beat(4)1
Avg EPS beat(4)-6.92%
Min EPS beat(4)-20.27%
Max EPS beat(4)7.63%
EPS beat(8)1
Avg EPS beat(8)-19.76%
EPS beat(12)1
Avg EPS beat(12)-20.47%
EPS beat(16)5
Avg EPS beat(16)-12.49%
Revenue beat(2)1
Avg Revenue beat(2)-1.1%
Min Revenue beat(2)-5.11%
Max Revenue beat(2)2.91%
Revenue beat(4)2
Avg Revenue beat(4)-2.22%
Min Revenue beat(4)-8.16%
Max Revenue beat(4)2.91%
Revenue beat(8)3
Avg Revenue beat(8)-1.91%
Revenue beat(12)4
Avg Revenue beat(12)-1.2%
Revenue beat(16)8
Avg Revenue beat(16)12.76%
PT rev (1m)14.24%
PT rev (3m)16.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.28%
EPS NY rev (1m)1.27%
EPS NY rev (3m)-0.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.21%
Revenue NY rev (1m)1.16%
Revenue NY rev (3m)0.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 55.17 | ||
| Fwd PE | 44.49 | ||
| P/S | 6.76 | ||
| P/FCF | 39.54 | ||
| P/OCF | 23.06 | ||
| P/B | 4.71 | ||
| P/tB | N/A | ||
| EV/EBITDA | 31.2 |
EPS(TTM)3.5
EY1.81%
EPS(NY)4.34
Fwd EY2.25%
FCF(TTM)4.88
FCFY2.53%
OCF(TTM)8.37
OCFY4.34%
SpS28.56
BVpS40.96
TBVpS-5.68
PEG (NY)2.3
PEG (5Y)13.15
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.12% | ||
| ROE | 4.38% | ||
| ROCE | 5.06% | ||
| ROIC | 4.03% | ||
| ROICexc | 4.45% | ||
| ROICexgc | 14.12% | ||
| OM | 13.32% | ||
| PM (TTM) | 6.29% | ||
| GM | 43.4% | ||
| FCFM | 17.1% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexcg growth 3Y-36.77%
ROICexcg growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 6.04 | ||
| Debt/EBITDA | 4.17 | ||
| Cap/Depr | 112.63% | ||
| Cap/Sales | 12.22% | ||
| Interest Coverage | 2.09 | ||
| Cash Conversion | 121.31% | ||
| Profit Quality | 271.91% | ||
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | 3.91 |
F-Score5
WACC7.81%
ROIC/WACC0.52
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)-16.47%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%43.06%
EPS Next Y24.02%
EPS Next 2Y24.95%
EPS Next 3Y24.29%
EPS Next 5Y22.18%
Revenue 1Y (TTM)0.16%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%6.3%
Revenue Next Year9.64%
Revenue Next 2Y10.58%
Revenue Next 3Y10.89%
Revenue Next 5Y12.44%
EBIT growth 1Y-17.48%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year87.53%
EBIT Next 3Y36.62%
EBIT Next 5Y29.52%
FCF growth 1Y74.23%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y9.2%
OCF growth 3Y5.11%
OCF growth 5Y21.32%